ASSOCIATION OF LEPTINEMIA AND ADIPONECTINEMIA WITH CHRONIC KIDNEY DISEASE IN PATIENTS WITH METABOLIC SYNDROME AND NON-ALCOHOLIC FATTY LIVER DISEASE


Cite item

Full Text

Abstract

Aim. Study of associations of leptinemia, adiponectinemia and progression of non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD). Methods. 86 patients (64 male, 22 female; mean age 44+11 years) with metabolic syndrome, associated with NAFLD (ultrasound features of hepatic stetatosis and/or non-alcoholic steatohepatitis) were included into the study. Risk factors and plasma levels of leptin and adiponectin were determined.
Results. Patients with >3 signs of target organ damage (TOD) had the highest rate of non-alcoholic steatohepatitis (78% vs 39% in patients with 1 sign of TOD, р<0,05) and highest level of albuminuria (30,2 (17,3 - 48,0) vs 6,0 (4,3 - 9,0) mg/24 hours in group with 1 sign of TOD, p<0,05). Increase in number of signs of TOD was associated with elevation of leptin/adiponectin ratio. Group with NAFLD and CKD was characterized with elevation of elevation of fasting insulinemia, C-peptide level, HOMA-index and leptinemia. Leptinemia directly correlated with body mass index, systolic BP, fasting insulinemia, C-peptide level, HOMA-index and albuminuria. Plasma level of adiponectin inversely correlated with intima-media thickness of common carotid artery. Plasma adiponectin level directly correlated with HDL plasma level, leptinemia and DeRitis ratio
Conclusion. In metabolic syndrome NAFLD and CKD are associated; their progression is determined with adipokines disbalance and increase in insulin resistance.

References

  1. Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа Медика 2008
  2. Лазебник Л.Б., Звенигородская Л.А., Егорова Е.Г. Метаболический синдром у пациентов с заболеваниями органов пищеварения. Тер. арх. 2007; 79(10): 9 - 13
  3. Sowers J.R. The cardiomethabolic syndrome and liver disease. J. Cardiomethab. Syndr. 2008; 3: 7-11
  4. Chang Y., Ryu S., Sung E. et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism. 2008; 57(4): 569-576
  5. Targher G., Bertolini L., Rodella S. et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008; 51(3): 444-450
  6. Antuna-Puente B., Feve B., Fellahi S. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008; 34(1): 2-11.
  7. Anubhuti, Arora S. Leptin and its metabolic interactions: an update. Diabetes Obes. Metab. 2008; 10(11): 973-993
  8. Han S.H., Sakuma I., Shin E.K., Koh K.K. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis. 2009; 52(2): 126-140.
  9. Комитет экспертов ВНОК. Диагностика и лечение метаболического синдрома. Российские рекомендации. М., 2009.
  10. Комитет экспертов РМОАГ/ВНОК. Диагностика и лечение артериальной гипертензии. (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010; 3: 5 - 26
  11. Hwang S.T., Cho Y.K., Yun J.W. et al. Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern. Med. J. 2010; 40(6): 437-442
  12. Kumagai S., Kishimoto H., Masatakasuwa et al. The leptin to adiponectin ratio is a good biomarker for the prevalence of metabolic syndrome, dependent on visceral fat accumulation and endurance fitness in obese patients with diabetes mellitus. Metab. Syndr. Relat. Disord. 2005; 3(2): 85-94
  13. Oda N., Imamura S., Fujita T. et al. The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism. 2008; 57(2): 268-273.
  14. Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol. 2006; 151:175-183.
  15. Kramer H, Luke A, Bidani A et al. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am J Kidney Dis. 2005; 46(4): 587-594.
  16. Foster MC, Hwang SJ, Larson MG, et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis. 2008; 52(1): 39-48
  17. Ikejima K., Okumura K., Lang T. et al. The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol. Res. 2005; 33(2): 151-154
  18. Мухин Н.А., Фомин В.В., Сагинова Е.А. и др. Эндотелиальная дисфункция и поражение почек при ожирении. Вестник РАМН 2006; 12: 25 - 31
  19. Pacifico L., Anania C., Martino F. et al. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology. 2010; 52(5): 1643-1651
  20. Sciacqua A., Perticone M., Miceli S. et al. Endothelial dysfunction and non-alcoholic liver steatosis in hypertensive patients. Nutr. Metab. Cardiovasc. Dis. 2010 Mar 11. [Epub ahead of print]
  21. Asferg C., Møgelvang R., Flyvbjerg A. et al. Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. Am. J. Hypertens. 2010; 23(3): 327-333
  22. Ma H., Gomez V., Lu L. et al. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2009; 24(2): 233-237
  23. Jiang L.L., Li L., Hong X.F. et al. Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels. Eur. J. Gastroenterol. Hepatol. 2009; 21(6): 662-666.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies